Quarterly report pursuant to Section 13 or 15(d)

Note 12 - License and Collaboration Agreement With Related Party (Details Textual)

v3.19.1
Note 12 - License and Collaboration Agreement With Related Party (Details Textual) - USD ($)
Sep. 27, 2018
Dec. 31, 2018
SK Group [Member] | DiaMedica [Member]    
Noncontrolling Interest, Ownership Percentage by Parent   8.40%
License Agreement [Member] | Ahon Pharma [Member]    
Revenue from Related Parties $ 500,000  
Collaboration Agreement, Non-refundable Payment Payable Upon Regulatory Clearance 4,500,000  
Collaboration Agreement, Additional Payment Upon Development and Sales Milestone $ 27,500,000  
Collaboration Agreement, Percent of Royalties Upon Development and Sales Milestones 10.00%